Literature DB >> 27732737

Tyrosine kinase inhibitor TKI-258 inhibits cell motility in oral squamous cell carcinoma in vitro.

Anna Cecília Dias Maciel Carneiro1, Isadora Caixeta da Silveira1, Arthur Silva Rezende1, Bruna Raphaela Oliveira Silva1, Virgínia Oliveira Crema1.   

Abstract

BACKGROUND: Oral squamous cell carcinoma is extremely invasive, and this behavior is regulated by binding of extracellular molecules to the cell membrane receptors. The TKI-258 inhibits phosphorylation of FGFRs VEGFRs and PDGFRs. Our aim was to analyze the effect of TKI-258 treatment in cell movement using SCC-4 cell line from human oral squamous cell carcinoma.
METHODS: F-actin was stained with rhodamine phalloidin, and confocal analysis was performed. The migration and invasion (membrane covered with Matrigel™ ) three-dimensional assays were performed, and control and cells treated with TKI-258 that migrated through the membrane were counted after 24 h.
RESULTS: Control cells presented abundant cytoplasm with F-actin wide distributed and evident cell cortex; however, treated (1, 5 and 10 μM TKI-258) cells showed round morphology, scanty cytoplasm, F-actin disorganized and preserved cell cortex. TKI-258 (1, 5, and 10 μM) treatment inhibits migrating cells (ANOVA, F = 97.749, d.f. = 3, 10; P < 0.0001), and it was concentration dependent. Invading cell treated with 5 μM TKI-258 was significantly lower (t = 6.708, d.f. = 5, P < 0.001).
CONCLUSIONS: These results suggest that the tyrosine kinase inhibitor TKI-258 has an inhibitory effect on cell motility, affecting F-actin, cell migration, and cell invasion, and probably, these processes are regulated by signaling pathways FGFRs and/or PDGFRs and/or VEGFRs.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  TKI-258; cell invasion; cell migration; oral squamous cell carcinoma; tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27732737     DOI: 10.1111/jop.12511

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  1 in total

Review 1.  Thymoquinone, as a Novel Therapeutic Candidate of Cancers.

Authors:  Belal Almajali; Hamid Ali Nagi Al-Jamal; Wan Rohani Wan Taib; Imilia Ismail; Muhammad Farid Johan; Abd Almonem Doolaanea; Wisam Nabeel Ibrahim
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.